Abstract

We report that bacterial RNA polymerase (RNAP) is the functional cellular target of the depsipeptide antibiotic salinamide A (Sal), and we report that Sal inhibits RNAP through a novel binding site and mechanism. We show that Sal inhibits RNA synthesis in cells and that mutations that confer Sal-resistance map to RNAP genes. We show that Sal interacts with the RNAP active-center 'bridge-helix cap,' comprising the 'bridge-helix N-terminal hinge,' 'F-loop,' and 'link region.' We show that Sal inhibits nucleotide addition in transcription initiation and elongation. We present a crystal structure that defines interactions between Sal and RNAP and effects of Sal on RNAP conformation. We propose that Sal functions by binding to the RNAP bridge-helix cap and preventing conformational changes of the bridge-helix N-terminal hinge necessary for nucleotide addition. The results provide a target for antibacterial drug discovery and a reagent to probe conformation and function of the bridge-helix N-terminal hinge.

Article and author information

Author details

  1. David Degen

    Rutgers University, Piscataway, United States
    Competing interests
    David Degen, patents pending on Sal derivatives and on bridge-helix-cap target.
  2. Yu Feng

    Rutgers University, Piscataway, United States
    Competing interests
    Yu Feng, patents pending on Sal derivatives.
  3. Yu Zhang

    Rutgers University, Piscataway, United States
    Competing interests
    Yu Zhang, patents pending on Sal derivatives.
  4. Katherine Y Ebright

    Rutgers University, Piscataway, United States
    Competing interests
    Katherine Y Ebright, patent pending on bridge-helix-cap target.
  5. Yon W Ebright

    Rutgers University, Piscataway, United States
    Competing interests
    Yon W Ebright, patents pending on Sal derivatives.
  6. Matthew Gigliotti

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  7. Hanif Vahedian-Movahed

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  8. Sukhendu Mandal

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  9. Meliza Talaue

    Rutgers University, Newark, United States
    Competing interests
    No competing interests declared.
  10. Nancy Connell

    Rutgers University, Newark, United States
    Competing interests
    No competing interests declared.
  11. Eddy Arnold

    Rutgers University, Piscataway, United States
    Competing interests
    No competing interests declared.
  12. William Fenical

    University of California, San Diego, La Jolla, United States
    Competing interests
    William Fenical, patent on SalA and SalB; patent pending on Sal derivatives.
  13. Richard H Ebright

    Rutgers University, Piscataway, United States
    For correspondence
    ebright@waksman.rutgers.edu
    Competing interests
    Richard H Ebright, patents pending on Sal derivatives and on bridge-helix-cap target.

Reviewing Editor

  1. Gisela Storz, National Institute of Child Health and Human Development, United States

Version history

  1. Received: February 2, 2014
  2. Accepted: April 18, 2014
  3. Accepted Manuscript published: April 30, 2014 (version 1)
  4. Version of Record published: May 21, 2014 (version 2)

Copyright

© 2014, Degen et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,102
    views
  • 425
    downloads
  • 59
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Degen
  2. Yu Feng
  3. Yu Zhang
  4. Katherine Y Ebright
  5. Yon W Ebright
  6. Matthew Gigliotti
  7. Hanif Vahedian-Movahed
  8. Sukhendu Mandal
  9. Meliza Talaue
  10. Nancy Connell
  11. Eddy Arnold
  12. William Fenical
  13. Richard H Ebright
(2014)
Transcription inhibition by the depsipeptide antibiotic salinamide A
eLife 3:e02451.
https://doi.org/10.7554/eLife.02451

Share this article

https://doi.org/10.7554/eLife.02451

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article

    Mediator of ERBB2-driven Cell Motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Isabelle Petit-Hartlein, Annelise Vermot ... Franck Fieschi
    Research Article

    NADPH oxidases (NOX) are transmembrane proteins, widely spread in eukaryotes and prokaryotes, that produce reactive oxygen species (ROS). Eukaryotes use the ROS products for innate immune defense and signaling in critical (patho)physiological processes. Despite the recent structures of human NOX isoforms, the activation of electron transfer remains incompletely understood. SpNOX, a homolog from Streptococcus pneumoniae, can serves as a robust model for exploring electron transfers in the NOX family thanks to its constitutive activity. Crystal structures of SpNOX full-length and dehydrogenase (DH) domain constructs are revealed here. The isolated DH domain acts as a flavin reductase, and both constructs use either NADPH or NADH as substrate. Our findings suggest that hydride transfer from NAD(P)H to FAD is the rate-limiting step in electron transfer. We identify significance of F397 in nicotinamide access to flavin isoalloxazine and confirm flavin binding contributions from both DH and Transmembrane (TM) domains. Comparison with related enzymes suggests that distal access to heme may influence the final electron acceptor, while the relative position of DH and TM does not necessarily correlate with activity, contrary to previous suggestions. It rather suggests requirement of an internal rearrangement, within the DH domain, to switch from a resting to an active state. Thus, SpNOX appears to be a good model of active NOX2, which allows us to propose an explanation for NOX2’s requirement for activation.